BioWorld

April 29, 2002

View Archived Issues

FDA Nixes Cellegy Pain Drug; Stock Takes Half-Off Nosedive

Cellegy Pharmaceuticals Inc.’s stock tumbled more than 50 percent on news that the company is withdrawing the new drug application for Cellegesic, its nitroglycerin ointment for the treatment of pain from anal fissures. (BioWorld Today) Read More

Senators Want To Close Gaps In Generic Drug Legislation

Read More

Hirschsprung Disease Gene Find Is First Complete Dissection Of Multifactorial Genetic Disorder

Read More

IDEC, Seikagaku Add $34M Extension To IDEC-152 Deal

Read More

Other News To Note

Read More

BIO Names Specter, Harkin Top Legislators Of The Year

Read More

Appointments And Advancements

Read More

Quarterly Earnings Reports

Read More